Effect of peritoneal dialysis solution type on serum lipid levels in end-stage renal disease.
Among the different cardiovascular risk factors, lipid abnormalities dominate the high mortality in chronic ambulatory peritoneal dialysis patients. So far, no data comparing the effect of standard glucose-containing, amino acid-containing, and icodextrin-containing peritoneal dialysis solutions on serum lipid concentrations in a chronic ambulatory peritoneal dialysis population are available. To determine the effect of peritoneal dialysis solutions on parameters of lipid metabolism, 67 subjects who had continued their usual dialysis for the last six months were enrolled in the study. Group A consisted of 18 patients who were receiving only glucose-based peritoneal dialysis solutions, group B consisted of 18 patients who were receiving glucose and amino acid-based peritoneal dialysis solutions, and group C consisted of 31 patients who were receiving glucose and icodextrin-based peritoneal dialysis solutions. Serum lipid parameters including total cholesterol, low-density lipoprotein, high-density lipoprotein, triglyceride, and lipoprotein (a) were determined in all groups. No significant difference in serum lipid parameters was found between groups A, B, and C. These results demonstrate the lack of the effect of amino acid or icodextrin-based peritoneal solutions on dyslipidemia of CAPD patients.
Kanbay
M
M
Fatih University Medical School, Department of Nephrology, Ankara, Turkey.
Bavbek
N
N
Delibasi
T
T
Koca
C
C
Kaya
A
A
Altay
M
M
Akcay
A
A
Duranay
M
M
Yigitoglu
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000596:Amino Acids / Q000494:pharmacology; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003430:Cross-Sectional Studies; D015314:Dialysis Solutions / Q000009:adverse effects / Q000494:pharmacology*; D050171:Dyslipidemias / Q000097:blood / Q000209:etiology; D005260:Female; D005936:Glucans / Q000494:pharmacology; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D000077607:Icodextrin; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy*; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D000596:Amino Acids; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015314:Dialysis Solutions; D005936:Glucans; D008055:Lipids; D017270:Lipoprotein(a); D014280:Triglycerides; D000077607:Icodextrin; D005947:Glucose